Skip to content

CG Oncology

US · CGON #1929 by market cap Listed 2024
79.47 -2.43 -2.97%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 6.71 Expensive vs history 91st percentile
5-year average 1.74 · #423 of 514 in Biotechnology
P/E ratio -26.96 In line with history 47th percentile
5-year average -26.27 · forward -28.38
P/S ratio 1,077.74 Cheap vs history 11th percentile
5-year average 3,729.78 · forward 194.53 · #352 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
CG Oncology (CGON) 7.10B -28.79 7.16 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value70.80 Economic moatNone UncertaintyHigh

Trading 10.9% above Morningstar's fair value estimate.

Fair value

CG Oncology Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 5% premium over our quantitative fair value estimate of $70.80 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's lack of profitability decreases our quantitative valuation. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's earnings yield of -2.9% sits in the bottom 30% globally. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.

The firm's liquidity is an additional cause for concern. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, ranks in the top 40% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. This characteristic further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

CG Oncology discussion 0 comments

Add a comment